4R

Akeso IncDUS Akeso Stock Report

Last reporting period 31 Dec, 2023

Updated 13 Nov, 2024

Last price

Market cap $B

7.022

Middle

Exchange

XDUS - Boerse Duesseldorf

4RY.DU Stock Analysis

4R

Uncovered

Akeso Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

110/100

High score

Market cap $B

7.022

Dividend yield

Shares outstanding

837.61 B

Akeso, Inc. Is an investment company, which engages in the research and development, production, and sale of biopharmaceuticals products. The company is headquartered in Zhongshan, Guangdong. The company went IPO on 2020-04-24. The firm is dedicated to addressing global unmet medical needs in oncology, immunology and other therapeutic areas. The firm's main products include AK104, AK105, AK112 and AK109. The firm conducts its businesses within the China market and to overseas markets.

View Section: Eyestock Rating